Royal Bank of Canada lowered its position in Pediatrix Medical Group, Inc. (NYSE:MD – Free Report) by 91.6% during the first quarter, Holdings Channel reports. The institutional investor owned 6,989 shares of the company’s stock after selling 76,035 shares during the quarter. Royal Bank of Canada’s holdings in Pediatrix Medical Group were worth $149,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of MD. Burney Co. acquired a new position in shares of Pediatrix Medical Group during the first quarter worth $1,129,000. Jennison Associates LLC acquired a new stake in Pediatrix Medical Group in the fourth quarter worth about $768,000. Renaissance Technologies LLC boosted its holdings in Pediatrix Medical Group by 12.9% in the first quarter. Renaissance Technologies LLC now owns 1,532,300 shares of the company’s stock worth $32,776,000 after acquiring an additional 174,600 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of Pediatrix Medical Group by 139.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 69,069 shares of the company’s stock worth $1,493,000 after acquiring an additional 40,176 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in shares of Pediatrix Medical Group by 7,643.2% during the first quarter. Fifth Third Bancorp now owns 62,333 shares of the company’s stock worth $1,333,000 after acquiring an additional 61,528 shares during the last quarter. Institutional investors own 97.71% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts recently commented on the stock. UBS Group increased their price objective on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Jefferies Financial Group downgraded shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating and boosted their target price for the stock from $27.00 to $28.00 in a research report on Wednesday, August 19th. Weiss Ratings downgraded Pediatrix Medical Group from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 25th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $25.00 price target on shares of Pediatrix Medical Group in a research report on Wednesday, August 5th. Finally, Mizuho set a $24.00 price objective on Pediatrix Medical Group in a report on Friday, May 8th. Seven equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, Pediatrix Medical Group currently has a consensus rating of “Hold” and a consensus target price of $25.00.
Pediatrix Medical Group Stock Up 0.2%
Shares of NYSE MD opened at $26.66 on Monday. Pediatrix Medical Group, Inc. has a 52-week low of $15.69 and a 52-week high of $27.94. The company’s 50-day simple moving average is $26.06 and its 200-day simple moving average is $23.19. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.45. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of 12.76 and a beta of 0.66.
Pediatrix Medical Group (NYSE:MD – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. The business had revenue of $487.78 million during the quarter, compared to analyst estimates of $478.49 million. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.53 earnings per share. Equities analysts predict that Pediatrix Medical Group, Inc. will post 2.17 EPS for the current fiscal year.
Pediatrix Medical Group Profile
Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.
Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.
Featured Articles
- Five stocks we like better than Pediatrix Medical Group
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pediatrix Medical Group, Inc. (NYSE:MD – Free Report).
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
